HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Semaglutide linked to 20-46% lower Alzheimer's-related dementia risk in type 2 diabetes

Louis Nervegna · Jun 30, 2025 · ♥ 11 reactions · 4 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Brain health & dementia
AI summary & key facts

Louis argues the real headline is that calorie restriction is associated with lower dementia risk since GLP-1 drugs act as calorie restriction in a pill. The shared report states semaglutide was associated with a 20-46% reduced risk for AD-related dementia in type 2 diabetes versus other antidiabetic drugs, strongest for vascular dementia.

The headline should really read:

Calorie Restriction Associated with Lower Dementia Risk

Because that is how GLP-1 agonist drugs really work. It is calorie restriction in a pill.

The widespread use of these drugs is finally giving us reliable data on how well calorie restriction actually works in humans. We’ve had reliable data on CR in animals for many decades, but virtually none in humans. This is finally changing thanks to these new drugs!

#glp1HD #calorierestrictionHD #dementiaHD #alzheimersHD

Research cited

Shared from Medscape · original post

Semaglutide was associated with a 20%-46% reduced risk for Alzheimer’s disease (AD)-related dementia in patients with type 2 diabetes (T2D) compared with other antidiabetic medications, with a particularly strong protective effect against vascular dementia, new research showed. Diabetes Drug Tied to Decreased Dementia Risk in T2D (Medscape)

No photo description available.
← newer: Buck Institute: neurons burn sugar differently, hinting how older: Carotid plaque burden on ultrasound predicted mortality bett →